Poor immune response to inactivated COVID-19 vaccine in patients with hypertension
Author:
Yang Lei1, Zhang ZhiHuan2, Guo Qiao2, Yang Lei1, Ren Hong2
Affiliation:
1. the Second Affiliated Hospital of Chongqing Medical University 2. Infectious Diseases
Abstract
Abstract
Purpose: The safety and efficacy of vaccination in people with hypertension (HTN) is important. There are currently just a few data on the immunogenicity and safety of inactivated SARS-CoV-2 vaccinations in hypertension patients.
Methods: After receiving a two-dose immunization, 94 hypertension patients and 74 healthy controls(HCs) in this study, the evaluation included looking at antibodies(Abs) against receptor binding domain (RBD) IgG, neutralizing antibodies(NAbs), RBD-specific B cells and memory B cells(MBCs).
Results: There was no discernible difference in the overall adverse events(AEs) over the course of seven or thirty days between HTN patients and HCs. HTN patients had lower frequencies of RBD-specific memory B cells and the seropositivity rates and titers of Abs compared to HCs(all, p < 0.05). HTN patients may exhibit comparable immunological responses in with or without concomitant cardiovascular and cerebrovascular conditions(CCVD). We again discovered a correlation between a weak Ab response and the interval time following a two-dose immunization.
Conclusion: Inactivated COVID-19 vaccinations were safe in hypertension patients, however humoral immune was limited.
Publisher
Research Square Platform LLC
Reference34 articles.
1. 1. Cooper, T. J., Woodward, B. L., Alom, S., & Harky, A. (2020). Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV medicine, 21(9), 567–577. https://doi.org/10.1111/hiv.12911 2. 2. Xu, G., Yang, Y., Du, Y., Peng, F., Hu, P., Wang, R., Yin, M., Li, T., Tu, L., Sun, J., et al. (2020). Clinical Pathway for Early Diagnosis of COVID-19: Updates from Experience to Evidence-Based Practice. Clinical reviews in allergy & immunology, 59(1), 89–100. https://doi.org/10.1007/s12016-020-08792-8 3. 3. Rifai, A., Wahono, C. S., Pratama, M. Z., Handono, K., Susianti, H., Iskandar, A., Diyah, N., Santoningsih, D., Samsu, N., & Gunawan, A. (2022). Association Between the Effectiveness and Immunogenicity of Inactivated SARS-CoV2 Vaccine (CoronaVac) with the Presence of Hypertension among Health Care Workers. Clinical and experimental hypertension (New York, N.Y. : 1993), 44(3), 233–239. https://doi.org/10.1080/10641963.2021.2022687 4. 4. Pranata, R., Lim, M. A., Huang, I., Raharjo, S. B., & Lukito, A. A. (2020). Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. Journal of the renin-angiotensin-aldosterone system : JRAAS, 21(2), 1470320320926899. https://doi.org/10.1177/1470320320926899 5. 5. Lu, J., Lu, Y., Wang, X., Li, X., Linderman, G. C., Wu, C., Cheng, X., Mu, L., Zhang, H., Liu, J., et al. (2017). Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet (London, England), 390(10112), 2549–2558. https://doi.org/10.1016/S0140-6736(17)32478-9
|
|